Sequence: rrrrrrrrXB
| Experiment Id | EXP001215 |
|---|---|
| Paper | Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid compositio |
| Peptide | r8 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 1–10 µM (splice correction, 24 h); 2 µM (uptake assay, 24 h) |
| Rna Concentration | 1–10 µM (conjugate, 24 h); 2 µM (uptake assay, 24 h) |
| Mixing Ratio | 1:1 (covalent peptide–PMO conjugate) |
| Formulation Format | covalent peptide–PMO conjugate |
| Formulation Components | CPP–PMO conjugate (amide linker); uptake assays used CPP–PMOF (3'-carboxyfluorescein-tagged PMO) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa pLuc705 (splice-correction assay); HepG2 (toxicity subset) |
| Animal Model | |
| Administration Route | |
| Output Type | splice correction (luciferase reporter) |
| Output Value | |
| Output Units | |
| Output Notes | Relative luciferase activity (RLU/µg protein) after 24 h treatment in OptiMEM ± serum; uptake quantified by flow cytometry (mean fluorescence) using CPP–PMOF. |
| Toxicity Notes | No detectable cytotoxicity up to 10 µM; at higher concentrations (20–60 µM) time- and concentration-dependent toxicity mainly observed for (RX)8–PMO and (RXR)4–PMO; others largely non-toxic in assays reported. |
| Curation Notes |